1/30
03:14 pm
ovid
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? [Yahoo! Finance]
Low
Report
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? [Yahoo! Finance]
1/26
11:06 pm
ovid
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots [Seeking Alpha]
Medium
Report
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots [Seeking Alpha]
12/27
01:05 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at
Wall Street
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at
Wall Street
12/22
10:25 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.
12/22
08:02 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
High
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
12/18
09:05 am
ovid
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]
Low
Report
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]
12/18
08:00 am
ovid
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
High
Report
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
12/12
05:52 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/11
06:03 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
12/2
07:00 am
ovid
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
High
Report
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
11/24
07:19 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/18
07:21 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
11/17
08:06 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.